Last updated 17 days ago

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

1000 patients around the world
Available in Spain, United States, Mexico, Peru, Brazil
Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
AstraZeneca
1000Patients around the world
This study is for people with
Cervical cancer
Requirements for the patient
From 15 Years
Female
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy